Maxime Verhoeven

98 Chapter 5 Supplementary Table S5 Comparative treatment effects of different TCZ-regimens on preventing radiographic progression in established RA, stratified analyses. total SvdH Erosions JSN total SvdH Erosions JSN Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) TCZ vs. TCZ+MTX 1 Effect in patients with low baseline damage # Effect in patients with high baseline damage $ Treatment (TCZ) 0.99 (0.79 to 1.23) 1.00 (0.86 to 1.17) 0.95 (0.84 to 1.08) 0.86 (0.68 to 1.10) 0.89 (0.73 to 1.08) 0.93 (0.73 to 1.18) Effect in patients with shorter disease duration # Effect in patients with longer disease duration $ Treatment (TCZ) 0.83 (0.64 to 1.06) 0.86 (0.71 to 1.03) 0.90 (0.73 to 1.12) 1.04 (0.84 to 1.30) 1.04 (0.87 to 1.25) 1.00 (0.82 to 1.22) Effect in patients with low baseline disease activity # Effect in patients with high baseline disease activity $ Treatment (TCZ) 1.02 (0.81 to 1.28) 0.96 (0.81 to 1.14) 1.02 (0.84 to 1.25) 0.84 (0.65 to 1.07) 0.99 (0.80 to 1.22) 0.82 (0.66 to 1.02) Number of patients in low level baseline joint damage subgroup; 96 in TCZ vs. 110 in TCZ+MTX, number of patients in high level baseline joint damage subgroup; 105 in TCZ vs. 106 in TCZ+MTX. Number of patients in low level baseline disease duration subgroup; 103 in TCZ vs. 105 in TCZ+MTX, number of patients in high level baseline disease duration subgroup; 99 in TCZ vs. 110 in TCZ+MTX. Number of patients in low level baseline DAS28 subgroup; 103 in TCZ vs. 104 in TCZ+MTX, number of patients in high level baseline DAS28 subgroup; 99 in TCZ vs. 111 in TCZ+MTX. TCZ= tocilizumab; MTX= methotrexate; DAS28= disease activity score assessing 28 joints; SvdH= Sharp van der Heijde; JSN= joint space narrowing. $ Subgroup baseline SvdH score/disease duration in years/DAS28 > median; # Subgroup baseline SvdH score/ disease duration in years/DAS28 ≤ median 1 = cut-off SvdH score of 28.5, disease duration of 5.46 years, baseline DAS28 of 6.37